1IOVA Stock Overview

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. More details

1IOVA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 92.6% below our estimate of its fair value

Earnings are forecast to grow 63.75% per year

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Iovance Biotherapeutics, Inc. Competitors

Philogen

BIT:PHIL

€878.3m

Geron

NasdaqGS:GERN

US$878.9m

Day One Biopharmaceuticals

NasdaqGS:DAWN

US$803.7m

Ulisse Biomed

BIT:UBM

€17.9m

Price History & Performance

Summary of share price highs, lows and changes for Iovance Biotherapeutics
Historical stock prices
Current Share Price	US$2.88
52 Week High	US$0
52 Week Low	US$0
Beta	1.06
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	1IOVA	IT Biotechs	IT Market
7D	0%	6.1%	3.0%
1Y	n/a	7.0%	12.6%

Return vs Industry: Insufficient data to determine how 1IOVA performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1IOVA performed against the Italian Market.

Price Volatility

Is 1IOVA's price volatile compared to industry and market?
1IOVA volatility
1IOVA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.2%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1IOVA's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1IOVA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	838	Frederick Vogt	www.iovance.com

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen.

Iovance Biotherapeutics, Inc. Fundamentals Summary

How do Iovance Biotherapeutics's earnings and revenue compare to its market cap?
1IOVA fundamental statistics
Market cap	€1.01b
Earnings (TTM)	-€328.82m
Revenue (TTM)	€144.96m

7.0x

P/S Ratio

-3.1x

P/E Ratio

Is 1IOVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1IOVA income statement (TTM)
Revenue	US$164.07m
Cost of Revenue	US$124.00m
Gross Profit	US$40.08m
Other Expenses	US$412.25m
Earnings	-US$372.18m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)	-1.14
Gross Margin	24.43%
Net Profit Margin	-226.84%
Debt/Equity Ratio	0.1%

How did 1IOVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/05 19:27
End of Day Share Price	2025/05/05 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Iovance Biotherapeutics, Inc. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Madhu Kumar	Baird
Colleen Kusy	Baird
Peter Lawson	Barclays

Iovance Biotherapeutics BIT:1IOVA Stock Report